U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    110.47
    +2.04 (+1.88%)
     
  • Gold

    1,807.10
    +5.60 (+0.31%)
     
  • Silver

    19.86
    +0.20 (+1.01%)
     
  • EUR/USD

    1.0428
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • GBP/USD

    1.2110
    +0.0007 (+0.06%)
     
  • USD/JPY

    135.7100
    +0.5350 (+0.40%)
     
  • BTC-USD

    19,700.16
    +566.43 (+2.96%)
     
  • CMC Crypto 200

    427.20
    +7.06 (+1.68%)
     
  • FTSE 100

    7,232.65
    +64.00 (+0.89%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million.

  • "This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue to work with our advisors to evaluate additional strategic alternatives for Catalyst," said Nassim Usman, CEO of Catalyst Biosciences.

  • According to the Catalyst website, the complement regulating pipeline includes four preclinical phase candidates.

  • In March, Catalyst Biosciences regained full rights to CB 2782-PEG, a C3-degrader for dry age-related macular degeneration, from Biogen Inc (NASDAQ: BIIB).

  • After the transaction, Catalyst's product candidates consist of the coagulation-related assets marzeptacog alfa (activated) (MarzAA), dalcinonacog alfa (DalcA), and CB 2679d-GT.

  • MarzAA is an SQ administered next-generation engineered coagulation Factor VIIa for episodic bleeding and prophylaxis in subjects with rare bleeding disorders.

  • DalcA is a next-generation SQ administered FIX.

  • CB 2679d-GT is an AAV-based gene therapy construct harboring the DalcA sequence.

  • Price Action: CBIO shares are up 178.9% at $1.06 on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.